Anzeige
Mehr »
Login
Samstag, 15.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
JETZT ODER NIE…dieser Kurs ist ein absoluter EINSTIEGS-TRAUM!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4QB | ISIN: FI4000480454 | Ticker-Symbol: 0TN
Frankfurt
14.03.25
15:29 Uhr
2,350 Euro
-0,030
-1,26 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BIORETEC OY Chart 1 Jahr
5-Tage-Chart
BIORETEC OY 5-Tage-Chart
RealtimeGeldBriefZeit
2,2902,44014.03.
PR Newswire
151 Leser
Artikel bewerten:
(0)

Bioretec Ltd's Annual Report 2024 published

Finanznachrichten News

Bioretec Ltd Press Release 14 March 2025 at 7:00 p.m. EET

TAMPERE, Finland, March 14, 2025 /PRNewswire/ -- Bioretec Ltd has today published its 2024 Annual Report. The Annual Report is attached to this release and also available in Finnish and English on the company's website at https://investors.bioretec.com/en/reports_and_presentations. Bioretec's previously published financial statements for 2024 are also available on the company's website.

Further enquiries

Alan Donze, CEO, +1 619 977 5285
Johanna Salko, CFO, +358 40 754 8172

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the?biological interface?of active implants?to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.?

Bioretec is?developing?the new RemeOs?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. The first RemeOs product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing - Better life. www.bioretec.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-ltd-s-annual-report-2024-published,c4119341

The following files are available for download:

https://mb.cision.com/Public/20509/4119341/9b2d6753d360aa72.pdf

Annual Report 2024 Bioretec

Cision View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-annual-report-2024-published-302402090.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.